Check this box if no

UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549

lis	SION	OMB APPROVAL							
		OMB Number:	3235-0287						
SH	IIP	Expires:	December 31, 2014						
f 19	34, Section	Estimated average burden							
on 30(h) of the		hours per response	0.5						
	5. Relationship of Reporting Person(s) to								

 Ionger subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
 Tiled pursuant to Section 16(a) of the Securities Exchange Act of 17(a) of the Public Utility Holding Company Act of 1935 or Section Investment Company Act of 1940
 Investment Company Act of 1940
 Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]

Bowden Christopher			in any i biobin	AGIOS PHARMACEUTICALS INC [AGIO]	Issuer (Check all applicable) Director 10% Owner X Officer (give Other (specify title below) below) Chief Medical Officer				
	(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2014					
	(Street) CAMBRIDGE (City)	MA (State)	02139 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 				

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8) Code		4. Secu Acquired Dispose (Instr. 3	d (A) d of , 4 ar (A) or	or (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8		of and		6. Date Exercisable and Expiration Date (Month/Day/Year)		Date Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	\$ 35.16	05/31/2014		A		120,000		(1)	05/30/2024	Common stock	120,000	\$ 0	120,000	D	

Explanation of Responses:

1. This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

<u>/s/ Glenn Goddard, as</u> <u>Attorney-in-Fact for</u> <u>Christopher Bowden</u> ** Signature of Reporting Person

06/03/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.